Vivet Therapeutics is committed to developing an innovative liver-directed gene therapy platform for the treatment of rare and severe inherited metabolic disorders. The company's development strategy is to target the liver with a novel synthetic adeno associated virus to introduce therapeutic genes to hepatocytes. 

Vivet's focus is on developing innovative gene therapy technologies and treatments for Wilson disease, Progressive Familiar Intrahepatic Cholestasis, Cirtullinemia and other indications. Vivet's platform leverages new AAV-serotypes, advanced GMP manufacturing processes, disease models and innovative technologies to address current challenges in AAV-based gene therapy.

Type
Private
HQ
Paris, FR
Founded
2016
Size (employees)
13 (est)
Vivet Therapeutics was founded in 2016 and is headquartered in Paris, FR
Report incorrect company information

Vivet Therapeutics Office Locations

Vivet Therapeutics has an office in Paris
Paris, FR (HQ)
29 Rue Tronchet
Show all (1)
Report incorrect company information

Vivet Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

Vivet Therapeutics total Funding

$41 m

Vivet Therapeutics latest funding size

$40.95 m

Time since last funding

a year ago

Vivet Therapeutics investors

Vivet Therapeutics's latest funding round in May 2017 was reported to be $41 m. In total, Vivet Therapeutics has raised $41 m
Show all financial metrics
Report incorrect company information

Vivet Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Vivet Therapeutics Company Life and Culture

Report incorrect company information